drugset / Trial / NCT05491928

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

NCT05491928

Expanded access Available Matrix Biomed, Inc.

Summary

The objective is to provide terminally diagnosed patients with a last line of treatment while improving overall quality of life. Tempol can be added to any chemotherapy regimen to potentially reduce side effects and overcome chemoresistance.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tempol Small molecule